Refractory anemia with ring sideroblasts
ICD-10 D46.1 is a billable code used to indicate a diagnosis of refractory anemia with ring sideroblasts.
Refractory anemia with ring sideroblasts (RARS) is a subtype of myelodysplastic syndromes (MDS) characterized by ineffective hematopoiesis leading to anemia and the presence of ring sideroblasts in the bone marrow. Ring sideroblasts are erythroid precursors that exhibit abnormal iron accumulation, which can be identified through a Prussian blue stain. Patients typically present with symptoms of anemia, such as fatigue, pallor, and weakness. The condition is classified under neoplasms of uncertain behavior, as it has the potential to progress to acute myeloid leukemia (AML) in some cases. The diagnosis is made through a combination of clinical evaluation, blood tests, and bone marrow biopsy. Surveillance is crucial for monitoring disease progression and managing complications. Treatment options may include supportive care, such as blood transfusions and erythropoiesis-stimulating agents, as well as potential therapies targeting the underlying dysplastic process. The prognosis varies, and careful monitoring is essential to address any signs of transformation to more aggressive forms of hematologic malignancy.
Detailed reports of blood tests, bone marrow biopsy results, and treatment plans.
Diagnosis and management of patients presenting with unexplained anemia and abnormal blood counts.
Ensure accurate reporting of ring sideroblasts and any treatment-related complications.
Comprehensive documentation of disease progression, treatment regimens, and response to therapy.
Management of patients with MDS who may progress to acute leukemia.
Monitor for signs of transformation and document any changes in treatment strategy.
Used to monitor blood counts in patients with RARS.
Document the reason for the CBC and any abnormal findings.
Hematology specialists should ensure accurate interpretation of results.
The key diagnostic criteria for D46.1 include the presence of anemia, identification of ring sideroblasts in the bone marrow, and exclusion of other causes of anemia. Regular monitoring for disease progression is also essential.
